Fig. 6
hiHeps are validated for in vitro disease modeling of HBV infection. a Immunofluorescence staining of NTCP in hiHeps. b Dynamic gene expression analysis of NTCP in hiHeps cultured in HMM for 40 days by RT-qPCR. n = 3. Relative expression was normalized to hiHeps cultured for 10 days. c Immunofluorescence staining of HBcAg in hiHeps infected with HBV at a multiplicity of infection (MOI) of 300 at 20 dpi and in uninfected hiHeps. d Quantification of different HBV markers in hHPLCs, hiHeps and PHHs around 6 dpi and in uninfected hiHeps. n = 3 e-h Dynamic expression of different HBV markers in 36 days post infection. HBV proteins (e), HBV-RNA (f), supernatant HBV-DNA (g) and intracellular HBV-DNA (h) were analyzed in HBV-infected hiHeps and hiHeps treated with ETV, LAM and IFN-α. n = 3. i Southern blot analysis of cccDNA in hiHeps. Hirt DNA was extracted from three independent experiments and half of the Hirt DNA was treated with SpeI before southern blotting. j Gene expression analysis of key ISGs in HBV-infected hiHeps, HBV-infected hiHeps treated with IFN-α, uninfected hiHeps and uninfected hiHeps treated with IFN-α. n = 3. For all measurements, ‘n’ represents the number of biological replicates. The scale bars represent 50 μm. Data are presented as mean ± SEM
